By Nicholas G. Miller

Personalis shares rose after the Centers for Medicare & Medicaid Services expanded coverage for the company's NeXT Personal test to include immunotherapy monitoring for patients with late-stage solid tumors.

The stock gained 9.1% to $6.59 in premarket trading. Through Tuesday's close it was down 24% this year.

The test provides a high-resolution view of a patient's tumor profile including in an immunotherapy setting, where inflammatory responses can often complicate the interpretation of traditional scans.

That enables identification of which patients are responding to immunotherapy, which is "critical for optimizing therapeutic pathways, minimizing unnecessary toxicity, and managing the high costs associated with these advanced therapies," the company said.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

May 13, 2026 07:11 ET (11:11 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.